Young Su Noh
Director, Head of Clinical Research & Development Hanmi Pharm
Seminars
Wednesday 10th June 2026
Optimizing Strategy for 4-1BB Costimulatory Bispecifics to Maximize Anti-Tumor Effects While Managing Historical 4-1BB Safety Challenges
9:15 am
- Exploring BH3120, a bivalent bispecific antibody generated by Pentambody® platform targeting 4-1BB and PD-L1 simultaneously, with monovalent anti-4-1BB arm (moderate affinity) and anti-PD-L1 arm (high affinity)
- Discussing how in preclinical evaluations, BH3120 demonstrated a favorable safety profile with low risk of hepatotoxicity and robust antitumor activity across multiple tumor models, with enhanced activity observed in combination with PD-1 blockade
- Outlining how early clinical results indicate a favorable safety profile by mitigating the risk of hepatotoxicity and providing initial evidence of antitumor activity across a range of tumor types
